Singapore: RaQualia Pharma and Interprotein entered into a collaborative research agreement. The partnership will focus on drug discovery research for a specific protein-protein interaction (PPI) inhibitor in the disease domain of pain. 

Under the agreement, RaQualia and Interprotein will collaborate to identify new drug candidates, combining RaQualia's core expertise in drug discovery and development, and Interprotein's platform technology, Intendd, on in-silico screening of PPI inhibitors.

Interprotein will be eligible to receive upfront payment, contingency payment and further research milestones from RaQualia under the agreement. RaQualia will be eligible to receive the world-wide exclusive rights of all results from this collaborative research.